ERG and prostate cancer: Of these, overexpression of the ETS-related gene (ERG) [2,3], resulting from the fusion of ERG coding sequences to the androgen-responsive TMPRSS2 gene [4], represents the most common subtype, with a prevalence of approximately 50% in clinically localized prostate cancers [1,5-11].